Attached files
| file | filename |
|---|---|
| EX-99.1 - EXHIBIT 99.1 - Lexaria Bioscience Corp. | exhibit99-1.htm |
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
Current Report
Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934
| Date of Report (date of earliest event reported): March 8, 2016 | ||
| LEXARIA CORP.
(Exact name of registrant as specified in its charter) | ||
| Nevada (State or other jurisdiction of incorporation) |
000-52138 (Commission File Number) |
20-2000871 (IRS Employer Identification No.) |
| #950 – 1130 West Pender Street, Vancouver, British Columbia, Canada V6E 4A4 | ||
| Registrant's telephone number, including area code: (604) 602-1675 | ||
| (Former name or former address, if changed since last report.) | ||
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
| [ ] | Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
| [ ] | Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
| [ ] | Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d- 2(b)) |
| [ ] | Pre-commencement communications pursuant to Rule 13e-4(c) under Exchange Act (17 CFR 240.13e-4(c)) |
Item 5.02. Departure of Directors or Principal Officers; Election of Directors; Appointment of Principal Officers.
On March 8, 2016 the Board of Directors accepted the resignation of Thomas Ihrke as VP of US Operations of Lexaria Corp.
Item 7.01 Regulation FD Disclosure.
A copy of the news release announcing the resignation is filed as exhibit 99.1 to this current report and is hereby incorporated by reference.
TEM 9.01. FINANCIAL STATEMENTS AND EXHIBITS.
| Exhibit No. | Description |
| 99.1 | News Release dated March 8, 2016 |
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
Dated: March 8, 2016
| Lexaria Corp. | |
| (Signature) | By: “/s/ Chris Bunka” |
| Chris Bunka | |
| CEO |